Irinotecan Mylan Generics

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Mylan Generics, is a topoisomerase I inhibitor presented as an injection solution for intravenous infusion use. It treats metastatic colorectal cancer and other solid tumors as part of combination chemotherapy regimens.

GNH USA supplies Irinotecan Mylan Generics as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The product complies with European Union marketing authorisation standards and is manufactured under GMP conditions. It is distributed through a regulated supply chain to ensure quality and traceability.

Irinotecan is used in oncology to target rapidly dividing cancer cells, particularly in colorectal and other solid tumor regimens.

Metastatic colorectal cancer: improves overall survival when combined with fluoropyrimidine‑based chemotherapy. Adjuvant therapy for colon cancer: reduces risk of disease recurrence after surgical resection. Small cell lung cancer (in combination regimens): contributes to tumor control as part of multi‑drug chemotherapy. Other solid tumors (as part of combination chemotherapy): provides antitumor activity in a variety of malignancies.

Irinotecan may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting - Diarrhea (often delayed) - Fatigue - Neutropenia (low white blood cell count) - Alopecia (hair loss) - Abdominal cramping

Serious or Rare Side Effects: - Severe neutropenia with fever (febrile neutropenia) - Severe diarrhea leading to dehydration and electrolyte imbalance - Hepatotoxicity (elevated liver enzymes) - Allergic reactions including anaphylaxis - Severe abdominal pain - Blood clotting abnormalities

When using Irinotecan, careful monitoring and specific precautions are required.

Dose adjustment: reduce dose in patients with hepatic impairment. Monitoring: perform regular complete blood counts to detect neutropenia. Diarrhea management: initiate antidiarrheal therapy promptly and consider dose delay if severe. Pregnancy: contraindicated in pregnancy; avoid use due to fetal risk. Drug interactions: avoid concurrent strong CYP3A4 inhibitors that may increase SN‑38 exposure. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan interacts with several medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): may increase SN‑38 levels and toxicity. - UGT1A1*28 homozygous genotype: risk of severe neutropenia; consider alternative therapy. - Concurrent use with other myelosuppressive agents: heightened risk of bone marrow suppression.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin): may modestly raise exposure. - Anticholinergic agents (e.g., atropine): can mask early signs of cholinergic toxicity. - Warfarin: monitor INR as irinotecan may affect coagulation parameters.